Compare Amgen, Inc. (AMGN) vs ProShares Bitcoin ETF (BITO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ProShares Bitcoin ETF — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while ProShares Bitcoin ETF trades at $8.5. The key difference: Amgen, Inc. pays a 2.77% dividend while ProShares Bitcoin ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BITO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Crypto-linked |
52-Week High | $388.16 | $23.05 |
52-Week Low | $271.18 | $7.98 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BITO trades at $8.67, up 1.17% with neutral technical signals and bearish moving averages. The fund faces challenges as its 0.95% expense ratio and futures roll costs create a significant performance gap versus Bitcoin. Recent dividend distributions of $0.01-$0.02 provide minimal yield support amid a 46% price decline over eight months. Media coverage highlights structural inefficiencies and investor outflows during the crypto market downturn.
Outlook remains cautious with high fees eroding returns and Bitcoin correlation breakdown reducing defensive appeal. Key risks include sustained crypto winter pressures and competition from lower-cost ETF alternatives. Analyst sentiment is mixed with downgrades citing distribution unreliability and NAV erosion concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →
